AgomAb Therapeutics NV ADR AGMB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $9.22
- Day Range
- $8.92–9.49
- 52-Week Range
- $7.97–17.82
- Bid/Ask
- $8.56 / $9.92
- Shares Outstanding
- 49.25M
- Market Cap
- $447.17M
- Volume/Avg
- 102,314 / 137,419
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 62
- Website
- https://www.agomab.com
Valuation
|
Metric
|
AGMB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.56 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
AGMB
|
|---|---|
Quick Ratio | 12.55 |
Current Ratio | 12.88 |
Interest Coverage | −354.73 |
Quick Ratio
AGMB
Profitability
|
Metric
|
AGMB
|
|---|---|
Return on Assets (Normalized) | −26.49% |
Return on Equity (Normalized) | −32.04% |
Return on Invested Capital (Normalized) | −31.69% |
Return on Assets
AGMB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|&tm$T> | LOCK|FJ@$Z | $129B | |||
| Moderna Inc
MRNA
| LOCK|WJ@%fw< | LOCK|<tG | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|<&?<<b | LOCK|Zh#Xc | $77B | |||
| argenx SE ADR
ARGX
| LOCK|B%Qth< | LOCK|cpw | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|l$s!^x% | LOCK|p@# | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|gn!#>! | LOCK|&^#H^ | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|&$KcHB<^ | LOCK|SDJx | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|WNvBj!& | LOCK|j?p | $24B | |||
| Incyte Corp
INCY
| LOCK|W$zz!W | LOCK|h#m | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|@&>KYCc | LOCK|#j& | $14B |
United States